DCGI likely to approve phase 3 trial data of Covaxin on Tuesday

The Subject Expert Committee (SEC) under the drug regulator reviewed Covaxin's Phase III trial data on Tuesday and the vaccine's efficacy has turned out to be 77.8 per cent

The Drugs Controller General of India (DCGI) is likely to approve Phase III trial data of Covaxin on Tuesday, sources said.

The Subject Expert Committee (SEC) under the drug regulator reviewed Covaxin's Phase III trial data on Tuesday and the vaccine's efficacy has turned out to be 77.8 per cent.

Covaxin is an indigenous Covid-19 vaccine produced by Bharat Biotech. The Hyderabad-based company had submitted data from the Phase III clinical trials of Covaxin to DCGI over the weekend.

Also Read: Social media posts twisted facts, final product doesn't have newborn calf serum: Centre on Covaxin

The sources said that Bharat Biotech's 'pre-submission' meeting with the World Health Organization (WHO) will take place on Wednesday for approval for Covaxin.

Covaxin is one of the three Covid-19 vaccines which have been given authorisation in the country for vaccination against Covid-19.

The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR).

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!